Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment
- PMID: 32443469
- PMCID: PMC7281116
- DOI: 10.3390/pathogens9050385
Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment
Abstract
Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis (MTB) and it represents a persistent public health threat for a number of complex biological and sociological reasons. According to the most recent Global Tuberculosis Report (2019) edited by the World Health Organization (WHO), TB is considered the ninth cause of death worldwide and the leading cause of mortality by a single infectious agent, with the highest rate of infections and death toll rate mostly concentrated in developing and low-income countries. We present here the editorial section to the Special Issue entitled "Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment" that includes 7 research articles and a review. The scientific contributions included in the Special Issue mainly focus on the characterization of MTB strains emerging in TB endemic countries as well as on multiple mechanisms adopted by the bacteria to resist and to adapt to antitubercular therapies.
Keywords: M. tuberculosis; antitubercular drug discovery; antitubercular treatments; host-pathogen interactions; immune response; tuberculosis.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.Curr Pharm Des. 2014;20(27):4305-6. doi: 10.2174/1381612819666131118203915. Curr Pharm Des. 2014. PMID: 24245755
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
[Recent progress in mycobacteriology].Kekkaku. 2007 Oct;82(10):783-99. Kekkaku. 2007. PMID: 18018602 Japanese.
-
The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.Tuberculosis (Edinb). 2018 Dec;113:200-214. doi: 10.1016/j.tube.2018.10.009. Epub 2018 Oct 30. Tuberculosis (Edinb). 2018. PMID: 30514504 Review.
-
[Frontier of mycobacterium research--host vs. mycobacterium].Kekkaku. 2005 Sep;80(9):613-29. Kekkaku. 2005. PMID: 16245793 Japanese.
Cited by
-
Macrophage-targeted nanoparticles mediate synergistic photodynamic therapy and immunotherapy of tuberculosis.RSC Adv. 2023 Jan 11;13(3):1727-1737. doi: 10.1039/d2ra06334d. eCollection 2023 Jan 6. RSC Adv. 2023. PMID: 36712647 Free PMC article.
-
Emerging Extracellular Molecular Targets for Innovative Pharmacological Approaches to Resistant Mtb Infection.Biomolecules. 2023 Jun 16;13(6):999. doi: 10.3390/biom13060999. Biomolecules. 2023. PMID: 37371579 Free PMC article. Review.
-
Predictive value of systemic immune-inflammatory biomarkers for drug-induced liver injury in hepatitis B virus surface antigen positive tuberculosis patients: A retrospective observational study.Medicine (Baltimore). 2024 Nov 8;103(45):e40349. doi: 10.1097/MD.0000000000040349. Medicine (Baltimore). 2024. PMID: 39533543 Free PMC article.
-
MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature.Biomedicines. 2022 Nov 3;10(11):2793. doi: 10.3390/biomedicines10112793. Biomedicines. 2022. PMID: 36359313 Free PMC article. Review.
-
Clinical assistant decision-making model of tuberculosis based on electronic health records.BioData Min. 2023 Mar 16;16(1):11. doi: 10.1186/s13040-023-00328-y. BioData Min. 2023. PMID: 36927471 Free PMC article.
References
-
- World Health Organization . Global tuberculosis Report WHO 2018. Volume 69 WHO; Geneva, Switzerland: 2018.
-
- Political Declaration of the High-Level Meeting of the General Assembly on the Fight against Tuberculosis. [(accessed on 16 May 2020)];2018 Available online: https://digitallibrary.un.org/record/1649568.
-
- Treatment Action Group . Tuberculosis Research Funding Trends 2005–2017. Treatment Action Group; New York, NY, USA: 2018. [(accessed on 16 May 2020)]. Available online: https://www.treatmentactiongroup.org/wp-content/uploads/2018/11/tb_fundi....
-
- Mupfumi L., Mpande C.A., Reid T., Moyo S., Shin S.S., Zetola N., Mogashoa T., Musonda R.M., Kasvosve I., Scriba T.J., et al. Immune Phenotype and Functionality of Mtb-Specific T-Cells in HIV/TB Co-infected patients on antiretroviral treatment. Pathogens. 2020;9:180. doi: 10.3390/pathogens9030180. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources